EU/3/17/1967

Table of contents

About

On 17 January 2018, orphan designation (EU/3/17/1967) was granted by the European Commission to Millendo Therapeutics Ltd, United Kingdom, for N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt (also known as ATR-101) for the treatment of congenital adrenal hyperplasia.

The sponsorship was transferred to Millendo Therapeutics S.A.S. France, in April 2019.

Key facts

Active substance
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt
Disease / condition
Treatment of congenital adrenal hyperplasia
Date of first decision
17/01/2018
Outcome
Positive
EU designation number
EU/3/17/1967

Sponsor's contact details

Millendo Therapeutics S.A.S.
15 G Chemin du Saquin
69130 Ecully
France
Tel. + 33 4721 80924
E-mail: info@millendo.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating